A61P 25/30
Drugs for disorders of the nervous system: for treating abuse or dependence
Official title: for treating abuse or dependence
A61P25/30 (Drugs for disorders of the nervous system: for treating abuse or dependence) appears on 7,003 US grants and 10,736 published applications in this corpus.
Search patents in A61P- Granted patents
- 7,003
- Published applications
- 10,736
- Assignees
- 2,447
- Inventors
- 13,915
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 1 | 0 |
| 1978 | 7 | 0 |
| 1979 | 4 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 3 | 0 |
| 1984 | 3 | 0 |
| 1985 | 7 | 0 |
| 1986 | 4 | 0 |
| 1987 | 4 | 0 |
| 1988 | 4 | 0 |
| 1989 | 9 | 0 |
| 1990 | 13 | 0 |
| 1991 | 5 | 0 |
| 1992 | 13 | 0 |
| 1993 | 18 | 0 |
| 1994 | 25 | 0 |
| 1995 | 21 | 0 |
| 1996 | 33 | 0 |
| 1997 | 68 | 0 |
| 1998 | 50 | 0 |
| 1999 | 76 | 0 |
| 2000 | 77 | 0 |
| 2001 | 123 | 40 |
| 2002 | 160 | 240 |
| 2003 | 179 | 401 |
| 2004 | 186 | 534 |
| 2005 | 160 | 506 |
| 2006 | 252 | 512 |
| 2007 | 238 | 564 |
| 2008 | 275 | 626 |
| 2009 | 311 | 700 |
| 2010 | 384 | 863 |
| 2011 | 397 | 688 |
| 2012 | 428 | 593 |
| 2013 | 457 | 461 |
| 2014 | 435 | 480 |
| 2015 | 404 | 502 |
| 2016 | 318 | 417 |
| 2017 | 346 | 407 |
| 2018 | 294 | 350 |
| 2019 | 258 | 347 |
| 2020 | 212 | 327 |
| 2021 | 181 | 249 |
| 2022 | 154 | 214 |
| 2023 | 113 | 218 |
| 2024 | 117 | 215 |
| 2025 | 115 | 172 |
| 2026 | 51 | 110 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cobalt-porphyrin complexes for the inactivation of the biological activity of opioids15 Sep 2026US 12,734,146 B2The Government of the United States of America, as represented by the Secretary of the Navy
- Acetylcholinesterase inhibitor11 Aug 2026US 12,702,148 B2Taiko Pharmaceutical Co., Ltd.
- Abuse-resistant pharmaceutical composition for the treatment of opioid dependence11 Aug 2026US 12,702,666 B2Edenbridge Pharmaceuticals, LLC
- Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof11 Aug 2026US 12,703,687 B2Shanghai Zhimeng Biopharma, Inc.
- Modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester16 Jun 2026US 12,653,807 B2Novartis AG
- Rapid induction with monthly injectable buprenorphine extended-release8 Oct 2026US 2026/0306480 A1Indivior UK Limited
- Rapid induction with monthly injectable buprenorphine extended-release8 Oct 2026US 2026/0306481 A1Indivior UK Limited
- Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders8 Oct 2026US 2026/0308154 A1The Regents of the University of California
- Ingestible formulations comprising methylliberine and one or more sugars and their use to treat the adverse effects of alcohol consumption1 Oct 2026US 2026/0294917 A1Lucid Psycheceuticals Inc.
- Combinations including methocinnamox24 Sep 2026US 2026/0284035 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Gum pad for delivery of medication to mucosal tissues1,140US 6,319,510 B12001
- Electronic atomization cigarette779US 7,832,410 B2Best Partners Worldwide Limited · 2010
- Method of preventing abuse of opioid dosage forms391US 6,228,863 B1Euro-Celtique S. A. · 2001
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009
- Tamper-resistant oral opioid agonist formulations343US 6,696,088 B2Euro-Celtique S. A. · 2004